A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deupirfenidone (Primary) ; Pirfenidone
Indications Idiopathic pulmonary fibrosis
Focus Registrational; Therapeutic Use
Acronyms ELEVATE
Sponsors PureTech Health

Most Recent Events

16 Apr 2024 Status changed from recruiting to active, no longer recruiting, according to a PureTech Health media release.
22 Feb 2024 Planned End Date changed from 1 Mar 2024 to 1 Aug 2025.
22 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Oct 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight